Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Omeros Corporation Q1 2026 Earnings Call - YARTEMLEA Launch Drives Strong Early Uptake and Cash Flow Positivity
Omeros Corporation delivered a robust first quarter 2026, driven by the successful launch of YARTEMLEA, the first and only approved treatment for TA-TMA. The company reported $11.1 million in gross re...
- YARTEMLEA launched in mid-January 2026, generating $11.1 million in gross revenues and $9.9 million in net revenues in Q1 2026, with gross-to-net adjustments held to a modest 11%.
- The company achieved cash flow positivity in the first quarter, just weeks after launch, and projects company-wide positive cash flow within 18 months.
- Adoption is accelerating ahead of plan: 30 unique accounts ordered YARTEMLEA by March 31, with 60% of the top 10 U.S. transplant centers securing P&T committee approvals.
- +7 more takeaways
HeartBeam Q1 2026 Earnings Call - Lean Commercial Rollout and Cash Runway Extended
HeartBeam is executing a capital-efficient, lean commercial rollout of its cable-free synthesized 12-lead ECG, securing anchor accounts in four key U.S. markets and validating a premium subscription m...
- HeartBeam secured its first commercial partnership with ClearCardio, establishing a presence in New York City, Dallas, and South Florida, and later added Atelier Health in Beverly Hills to cover Southern California.
- The company’s premium subscription model is priced between $750 and $1,000 annually, with early physician feedback indicating strong demand for the clinical-grade 12-lead ECG capability.
- HeartBeam is executing a lean commercial strategy, using a small team to validate the business model in four key geographies before scaling sales and clinical support in the second half of 2026.
- +7 more takeaways
Marchex Q1 2026 Earnings Call - Archenia Acquisition and AI Bundling Drive EBITDA Upgrade
Marchex reported a slight sequential revenue decline to $10.6 million in Q1 2026, but management pivoted sharply toward a higher-growth narrative centered on its pending Archenia acquisition and AI-dr...
- Revenue dipped slightly to $10.6 million in Q1 2026, down from $10.8 million in Q4 2025, due to legacy platform migration offsets partially masked by new sales and upsells.
- Management announced a significant EBITDA upgrade, guiding Q2 adjusted EBITDA to $1.6–$1.8 million, up from prior guidance of >$1 million.
- Standalone Q3 2026 adjusted EBITDA is now projected at $2 million or more, with combined Archenia EBITDA potentially reaching $2.5 million if the deal closes.
- +7 more takeaways
CytoSorbents Q1 2026 Earnings Call - DrugSorb-ATR FDA Pathway Clarified Amidst Geopolitical Headwinds
CytoSorbents reported a 2% year-over-year revenue increase to $8.9 million in Q1 2026, driven by strong 13% growth in direct international sales outside Germany, which was partially offset by a declin...
- Q1 2026 revenue reached $8.9 million, marking a 2% year-over-year increase, though this was down 7% on a constant currency basis.
- Direct international sales outside Germany grew 13% year-over-year, highlighting improved physician awareness and execution in new markets.
- German market sales declined year-over-year, but management reports improved sales force productivity and plans to selectively rebuild the team to drive future growth.
- +11 more takeaways
Journey Medical Q1 2026 Earnings Call - EMROSI Revenues Jump 21% as Reimbursement Wins Fuel Operating Leverage
Journey Medical delivered a strong first quarter with total revenues reaching $16 million, driven by a 200% year-over-year surge in EMROSI sales to $6.3 million. The company reported its third consecu...
- EMROSI revenues surged 200% year-over-year to $6.3 million, contributing to total net product revenue growth of 21% to $16 million.
- The company achieved positive adjusted EBITDA of $600,000 for the third consecutive quarter, reflecting improving operating leverage.
- Cash reserves increased to $27.2 million by quarter end, up from $24.1 million in December 2025.
- +7 more takeaways
Aytu Biopharma Q3 FY2026 Earnings Call - EXXUA Launch Accelerates With 26% Monthly Script Growth
Aytu Biopharma's first full commercial quarter for EXXUA, its novel antidepressant, delivered a 26% month-over-month script growth rate, climbing from 200 prescriptions in January to over 900 in April...
- EXXUA script volume surged 26% month-over-month in April, reaching over 920 prescriptions, up from 700 in March, signaling accelerating physician adoption.
- More than 1,300 prescriptions were written in Q3 by over 450 unique prescribers, representing 10-13% of the initial 3,500-4,000 targeted physician universe.
- EXXUA generated $2.4 million in net revenue for Q3, exceeding management's initial launch expectations and demonstrating strong early commercial traction.
- +7 more takeaways
Usio Q1 FY2026 Earnings Call - Record Revenue Growth Driven by PayFac and Real-Time Payments Momentum
Usio delivered a record first quarter for fiscal 2026, posting 16% year-over-year revenue growth to reach an all-time high. The company achieved positive GAAP net income, adjusted EBITDA, and operatin...
- Usio reported record quarterly revenue of $38.5 million (implied by 16% growth context), representing a 16% year-over-year increase and a new all-time high for the company.
- The company achieved positive GAAP net income of approximately $130,000, along with positive adjusted EBITDA and operating cash flow, signaling a successful transition to sustainable profitability.
- Card processing revenue surged 23% year-over-year to $9.7 million, driven primarily by the PayFac segment which now constitutes 78% of card revenues and is growing at a rate exceeding 20%.
- +9 more takeaways
Longeveron Q1 2026 Earnings Call - FDA Drops Pivotal Status for HLHS Trial, Shifts to Asset-Light Partnership Model
Longeveron is pivoting to an asset-light, partnership-driven strategy as it prepares for a critical regulatory juncture. The FDA has withdrawn pivotal status from the ELPIS II trial for laromestrocel ...
- CEO Stephen Willard completed a strategic review in February, transitioning Longeveron to an asset-light model focused on licensing partnerships for laromestrocel across all four development programs.
- The FDA withdrew pivotal status from the ELPIS II trial in hypoplastic left heart syndrome (HLHS), rejecting right ventricle ejection fraction (RVEF) as a valid primary efficacy endpoint.
- Management plans to submit a revised statistical analysis plan (SAP) to the FDA post-August 2026 data readout, focusing on composite endpoints like all-cause mortality and cardiac transplant-free survival.
- +7 more takeaways
Precigen Q1 2026 Earnings Call - PAPZIMEOS Revenue Surges 535% on Rapid Commercial Uptake
Precigen delivered a striking first quarter for its newly approved RRP therapy, PAPZIMEOS, with net product revenue jumping to $21.6 million from $3.4 million in the prior quarter. The acceleration re...
- PAPZIMEOS net product revenue surged 535% quarter-over-quarter to $21.6 million in Q1 2026, up from $3.4 million in Q4 2025.
- Total revenue reached $23.3 million, driven by strong commercial uptake of the newly approved RRP therapy.
- Operating loss improved to $6 million, with R&D expenses declining $4.8 million year-over-year as manufacturing costs are no longer expensed pre-approval.
- +11 more takeaways
MDxHealth Q1 2026 Earnings Call - Exiting Resolve UTI Business to Double Down on Prostate Cancer Diagnostics
MDxHealth is pulling the plug on its Resolve UTI test and closing its Plano, Texas lab to eliminate reimbursement uncertainty and refocus entirely on its prostate cancer precision diagnostics. The mov...
- MDxHealth is discontinuing its Resolve UTI test and closing its Plano, Texas laboratory to eliminate exposure to reimbursement uncertainty, particularly after Texas Medicare administrator Novitas Solutions reversed policy and sought $10.4 million in historical claim recoupments.
- Q1 2026 core prostate cancer revenue grew 11% year-over-year to $23.9 million on a pro forma basis, excluding the Resolve business entirely from the calculation.
- Pro forma gross margin for the quarter was 62.9%, down from 68% in Q1 2025, a decline management attributes to a shift in the mix between tissue-based and liquid-based testing.
- +7 more takeaways